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Preparations of the catalytic subunit of CAMP-dependent protein kinase from rabbit skeletal muscle, which appear to 
bc homogeneous by SDS-polyacrylamide gel electrophoresis, were often found to contain a hormone-like factor (HLF) 
which causes an immediate rise, then a decline of intracellular CAMP in a B-lymphoma cell line. Active HLF is released 
when the fractions that contain it in an inactive form are incubated with CAMP prior to chromatography, or passed 
through an immobilized CAMP column. HLF seems to be a peptide: it loses its cell-stimulating capability after proteolysis 
and has an apparent molecular mass of 2.2 - 2.5 kDa. 
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1. INTRODUCTION 
Following the isolation and characterization of a 
membranal proteinase which clips the catalytic 
subunit of CAMP-dependent protein kinase (PKA) 
with a unique biochemical specificity [l-3], and 
the finding that in cell membranes the proteinase 
faces the cell exterior [4], we considered a possible 
extracellular function for PKA [5,6]. While at- 
tempting to identify such a function, we observed 
that preparations of the catalytic subunit of PKA 
(purified from rabbit skeletal muscle [7]), which 
appeared to be homogeneous by SDS-PAGE and 
Coomassie blue staining, often contain a hormone- 
like factor (HLF) which brings about a rapid rise 
and a subsequent decline in the level of in- 
tracellular CAMP in a B-lymphoma cell line. This 
paper assigns the hormone-like activity to one (or 
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more) peptide (2.2-2.5 kDa) and provides 
evidence that HLF may exist in an inactive com- 
plex which copurifies with the holoenzyme of type 
I PKA, and that CAMP triggers its release in an ac- 
tive form. 
2. MATERIALS AND METHODS 
2.1. The B-lymphoma cell line (WEHI-231) 
The WEH1-231 cell line [8] was kindly provided by Professor 
Dov Zipori from the Weizmann Institute of Science, Rehovot. 
The cells were cultured at 37’C in tissue culture flasks in an 
RPMI-1640 medium containing heat-inactivated fetal calf 
serum (IO%), 2-mercaptoethanol (50 pM), penicillin (200 U/ 
ml), streptomycin (200 fig/ml) and neomycin (10 /g/ml). The 
culture atmosphere was composed of CO2 (7%) and humid air 
(93%). Cell preparations used (< lo6 cells/ml) were growing 
logarithmically and contained over 90% viable cells, as judged 
by standard trypan blue staining. Before challenging with HLF 
or a control hormone, the cells were ‘washed’ twice by cen- 
trifugation (5 min, 200 x g) at 22°C and resuspended in an 
RPMI-1640 medium (kept at 37°C) which contained no fetal 
calf serum, 2-mercaptoethanol or antibiotics. The final cell 
suspension had a cell density of 5 x 10’ cells/ml. 
2.2. Monitoring the cellular response to hormonal challenge [9/ 
Aliquots of the cell suspensions described above (200 pl) were 
incubated at 37°C for 60 min [9,10] before challenge with HLF. 
Samples (50 ~1) of the fractions assayed for HLF were added to 
these suspensions and cell stimulation was allowed to proceed 
at 37°C. At the indicated time of incubation, the cells were spun 
down (15 s, 12000 x g), the supernatant discarded and the 
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pellets (10’ cells) ruptured (to release their intracellular CAMP) 
by the addition of 50 pl of 0.1 N HCl and boiling (3 min at 
95°C) [ll]. The boiled samples were cooled, neutralized, and 
their CAMP was determined [12,13], using the assay kit provid- 
ed by Amersham. A control sample in which cells from the 
same cell suspension were challenged with DL-isoproterenol 
(final concentration IO-’ M) was routinely run alongside. 
2.3. Assays 
The following assays were carried out as described: PKA 
[14], CAMP [12,13], catecholamines [15]. 
2.4. Preparation of a crude extract of rabbit skeletal muscle 3. RESULTS AND DISCUSSION 
and its fractionation on DEAE-cellulose 
Rabbit skeletal muscle (5 kg) was homogenized in a Waring 
blender with 12.5 1 of an extracting solution containing EDTA 
(4 mM) and 2-mercaptoethanol (15 mM), pH 7.0. The 
homogenate was centrifuged (10 min 11000 x g), and the super- 
natant filtered through glass wool, followed by dilution with 
3 vols cold (4°C) deionized water containing 2-mercaptoethanol 
(15 mM). The conductivity of the resulting solution was ascer- 
tained to be 0.9-l .O mO_‘. DEAE-cellulose (DE-52) was wash- 
ed and pre-equilibrated with a buffer composed of 
4-morpholineethanesulfonic acid (5 mM), NaCl (9 mM), 
2-mercaptoethanol (15 mM), pH 6.5 (buffer A), allowed to set- 
tle, then 5 1 of the settled column material were added to the 
diluted supernatant mentioned above. The resulting suspension 
was stirred for 1 h (4°C) and then allowed to settle for another 
hour (4°C). The supernatant was discarded, the resin transfer- 
red to a sintered glass funnel and washed with buffer A till the 
absorbance of the washings at 280 nm was below 0.5. The resin 
(with the proteins adsorbed onto it) was packed in a column 
(10 x 80 cm) and a linear gradient from 9 to 500 mM NaCl in 
buffer A (total volume 10 I) was applied. Fractions (20 ml each) 
were collected and assayed as described in the legend to fig.1. 
The experiments described here stem from an 
unexpected observation that preparations of 
purified catalytic subunits of PKA, which were 
considered homogeneous on the basis of SDS- 
PAGE and Coomassie blue staining, were often 
found to stimulate WEHI- B-lymphoma cells, 
elevating and subsequently attenuating in- 
tracellular CAMP in a spike-like manner. Further- 
more, the intensity and pattern of response 
obtained with these catalytic subunit preparations 
(0.7-1.0 x 1O-6 M) was very similar to that ob- 
tained when the same cells were stimulated with a 
similar molar concentration of isoproterenol or 
with the peptide hormones ,&MSH, ACTH and 
VIP (rise of CAMP to 15-20 pmol/lO’ cells within 
0.5-1.0 min). Cell stimulation by the catalytic 
subunit preparations did not require ATP and 
Mg2+, indicating that the PKA preparation was 
not acting as a kinase. 
2.5. Chromatography on CM-Sephadex (CSO) 
CM-Sephadex (C50) was pre-equilibrated with buffer B com- 
posed of phosphate (30 mM), EDTA (1 mM) and DTT (1 mM), 
pH 6.7. 10 ml of the settled column material was added to the 
sample chromatographed (100 ml) and swirled overnight at 
4°C. The resin was then transferred to a sintered glass funnel 
and washed with buffer B until the absorbance at 280 and 
260 nm was below 0.01. The resin was packed into a column 
(2 x 50 cm) and a linear gradient of phosphate buffer 
(30-300 mM, total volume 80 ml) was applied. Fractions 
(2.2 ml) were collected and assayed as described in the legend 
to fig.2. 
neomycin) (Bio-Lab, Jerusalem); 2-mercaptoethanol (Merck); 
trypan blue (Fluka); DEAE-52 (Whatman); CM-Sephadex 
(C-50), Sephadex G-25 (fine), Sepharose 4B and Seph-CAMP 
(agarose-ethane-adenosine 3 ’ ,5 ‘-cyclic phosphate A&AMP, 
type 2, ethane spacer, 4.9 amol CAMP/ml) (Pharmacia); CAMP 
assay kit (TRK 432) and [y-32P]ATP (2000-3000 Ci/mmol) 
(Radiochemical Centre, Amersham). RPMI-1640 was obtained 
from the Biological Services Unit of the Weizmann Institute of 
Science, Rehovot. All other chemicals were of the best available 
grade from commercial sources. 
Now, the above-mentioned catalytic subunit of 
PKA was prepared from rabbit skeletal muscle 
following the method of Beavo et al. [7] which in- 
volves chromatography on DEAE-52 to resolve the 
type I and II holoenzymes (fig.l), dissociation of 
the holoenzymes with CAMP and isolation of the 
free catalytic subunit by preferential adsorption on 
carboxymethylcellulose or carboxymethyl- 
Sephadex (CM 50). Since the hormone-like activity 
described above was obtained with the catalytic 
subunit isolated from type I (but not type II) 
holoenzyme, and since it is known that the 
catalytic subunits of both holoenzyme types are 
identical, we suspected that the hormone-like ac- 
tivity is not an intrinsic property of the catalytic 
subunit itself but is rather due to a factor which 
copurifies with the catalytic subunit obtained from 
the type I holoenzyme. 
2.6. SDS-PAGE 
Polyacrylamide gel electrophoresis in the presence of SDS 
was carried out as in [16] using either lo%, or a gradient of 
7-20% polyacrylamide. The gels were fixed, stained with 
0.25% Coomassie blue and dried under vacuum. 
2.7. Chemicals, radiochemicals, era, culture media, assay kits 
and immobilized CAMP 
These were purchased from the following commercial 
sources: CAMP, cGMP, ATP, DL-isoproterenol, S. aureus V8 
protease (type XVII) and whole histone (Sigma); fetal calf 
serum and combined antibiotics (penicillin, streptomycin and 
We therefore returned to the previous purifica- 
tion step and attempted to identify the HLF by its 
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Fig.1. Chromatography of rabbit skeletal muscle extract on DEAE cellulose (DE-52). The following parameters were monitored: 
absorbance at 280 nm (0); conductivity (0); PKA activity (in the presence of 5 x 10e6 CAMP) (0); HLF activity (cell stimulation, 
1 min) (A). 
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Fig.2. Chromatography of pool 1 (fig.1) on CM-Sephadex (C50). Three samples (100 ml each) of pool 1 were incubated and swirled 
(30 min, 4°C) with either CAMP (final concentration 10m5 M), cGMP (final concentration 10m5 M) or no addition. Chromatography 
om”L’IS19ednahex was cariteb our as &esciloe&‘m sedilon2.T’neTrdllol~~_~a~m~rs were rn~~:rvl~~~~~try’~‘;~~#~zvrtmtl 
(measured in 50-~1 samples) (A); HLF activity (5021 samples used; cell stimulation: 1 min) (0). 
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cell-stimulating capability, assaying the various 
fractions within the type I holoenzyme peak and 
the fractions preceding it. As seen in fig. 1, none of 
these fractions contained a significant level of ac- 
tive HLF. However, when the fractions were 
pooled as indicated in fig.1 and subjected to 
chromatography on CM-Sephadex after pre- 
treatment with CAMP, we observed the release of 
several peaks of active HLF not only from pool 2 
but also from pool 1 (fig.2, left panel) which had 
no PKA activity (cf. fig. 1). To our surprise, no ac- 
tive HLF was observed when the CM-Sephadex 
chromatography was carried out without pre- 
incubation with CAMP (fig.2, center panel). In ad- 
dition, when CAMP was replaced by cGMP, the 
amount of active HLF released was negligible 
(fig.2, right panel). This relationship between 
CAMP and cGMP is reminiscent of the low relative 
efficacy of cGMP in dissociating PKA [17]. It 
should be noted that the high CAMP levels ob- 
tained upon exposure of the cells to the various 
fractions could not be attributed to a carry-over of 
CAMP from the pre-incubation step. As shown in 
fig.2 (left panel), the fractions that contained a 
high level of HLF had a very low CAMP content 
(1 pmol/50 ~1) prior to their addition to cells for 
the HLF assay. We also excluded the possibility 
that the response of the cells was due to 
catecholamines: using a sensitive fluorometric 
assay [15] it was shown that these fractions do not 
contain a level of catecholamines that could ac- 
count for the observed cellular stimulation. 
On the basis of the results presented above, and 
by analogy to the activation of PKA by CAMP 
[17], we postulated that HLF emerges from the 
DEAE-52 column in the form of an inactive com- 
plex, which is dissociated upon binding of CAMP, 
and releases HLF in an active form. To test this 
hypothesis we attempted to remove the presumed 
CAMP-binding inhibitor of HLF with an im- 
mobilized CAMP column. Indeed, passage of pool 
1 from fig.1 through such a column resulted in the 
release of active HLF (fig.3). A similar release of 
active HLF was not achieved with a control 
Sepharose 4B column (fig.3). 
To assess the chemical nature of the HLF, we ex- 
posed it to a proteolytic enzyme. As shown in 
fig.4, when the HLF fractions of the first peak in 
the left panel of fig.2 were subjected to proteolysis 
(1 h, 37°C) by V8 protease type XVII from S. 
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Fig.3. Release of active HLF by passage through an 
immobilized CAMP column. Two samples (10 ml each) of pool 
1 in fig.1 were incubated (16 h, 4°C) with either Seph-CAMP 
(agarose-ethane-adenosine 3 ’ ,5 ‘-cyclic phosphate) or Seph 
(Sepharose 4B) (in each case the volume of settled gel used was 
5 ml). The column material was then spun down, and the 
indicated volume of supernatant was assayed for HLF activity 
(cell stimulation, 1 min). Immobilized CAMP (0); Sepharose 
4B (0). 
aureus (final concentration 0.1 mg/ml), the HLF 
lost its activity and failed to stimulate WEHI- 
cells, suggesting that HLF is a polypeptide. When 
the same fractions were subjected to gel filtration 
on a pre-calibrated Sephadex G-25 (fine) column, 
two major activity peaks were obtained, with ap- 
parent molecular masses of 2.2 and 2.5 kDa 
(fig.5). 
Until now, mammalian cells were shown to con- 
tain two targets for CAMP: (i) PKA [ 181, whose ac- 
tivity is directly controlled by the binding of CAMP 
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Fig.4. Proteolytic degradation of HLF. A sample (1 .O ml) from 
the first peak of HLF activity (fig.2, left panel) was incubated 
(1 h, 37’C) either with V8 protease from S. aureus (final 
concentration 0.1 mg/ml) or with no addition. Aliquots (50 ~1) 
of both samples were assayed for HLF activity after the 
indicated cell stimulation times. Incubation mixture with V8 
protease (A); incubation mixture with no addition (control) 
(0). 
to implement the hormonal stimulation of cells, 
and (ii) CAMP phosphodiesterase, which is in- 
volved in the decomposition of CAMP to bring 
about the attenuation of such hormonal stimuli 
[ 191. The results presented above raise the 
possibility that there may be an additional target 
for CAMP - a complex between HLF and an in- 
hibitor which binds CAMP to release active HLF. 
If this complex is not the result of a fortuitous 
association between HLF and a CAMP-binding 
protein, and a fortuitous dissociation of this com- 
plex by a specific interaction with CAMP, then it 
might have a physiological assignment, for exam- 
ple in the amplification of a hormonal stimulus by 
an autocrine or paracrine mechanism [20]. In any 
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Fig.5. Apparent molecular mass of active HLF by gel filtration. 
A sample (1.5 ml) of the first peak of HLF activity (fig.2, left 
panel) was applied on a column of Sephadex G-25 (fine), pre- 
equilibrated and run at 0.5 ml/min (4°C) with a buffer 
composed of phosphate (30 mM), EDTA (1 mM) and DTT 
(1 mM), pH 6.7. Fractions (2 ml) were collected and assayed 
for HLF activity (cell stimulation, 1 min). The column was pre- 
calibrated with synthetic peptides of known molecular mass 
(inset); VIP (3323 Da); sequence l-20 of the a-subunit of the 
acetylcholine receptor (2940 Da); sequence 5-18 of the B- 
subunit of Shigella toxin (1546 Da); bacitracin (1500 Da); 
sequence 327-335 and 330-335 of the catalytic subunit of PKA 
(1205 and 810 Da, respectively), and sequence 12-18 of the B- 
subunit of Shigellu toxin (768 Da). 
event, the occurrence of a CAMP-triggered release 
of an active hormone-like factor is not only in- 
triguing but should be kept in mind when cells are 
exposed to media that contain CAMP and partially 
purified cellular constituents. 
Acknowledgements: This work was supported by grants from 
the Fund of Basic Research of the Israel Academy of Sciences, 
the Rockefeller-Weizmann Collaboration and the Armando 
Kaminitz Research Prize awarded to S.S. We thank Mrs Joan 
Glick for excellent secretarial assistance. S.S. is the incumbent 
of the Hella and Derrick Kleeman Chair in Biochemistry. 
249 
Volume 239, number 2 FEBS LETTERS November 1988 
REFERENCES [9] Zick, Y., Cesla, R. and Shaltiel, S. (1983) Biochim. Bio- 
phys. Acta 762, 355-365. 
[l] Alhanaty, E. and Shaltiel, S. (1979) Biochem. Biophys. [IO] Zick, Y., Cesla, R. and Shaltiel, S. (1978) FEBS Lett. 90, 
Res. Commun. 89, 323-332. 239-242. 
[2] Alhanaty, E., Patinkin, J., Tauber-Finkelstein, M. and 
Shaltiel, S. (1981) Proc. Natl. Acad. Sci. USA 78, 
3492-3495. 
[3] Alhanaty, E., Tauber-Finkelstein, M., Schmeeda, H. and 
Shaltiel, S. (1985) Curr. Top. Cell. Regul. 27, 267-277. 
[4] De Jonge, H., Schmeeda, H. and Shaltiel, S. (1987) Eur. 
J. Biochem. 169, 503-509. 
[5] Korc-Grodzicki, B., Riven-Kreitman, R., Tauber- 
Finkelstein, M. and Shaltiel, S. (1986) Proceedings of the 
Spetsai Summer Course on Signal Transduction and 
Protein Phosphorylation, Sept. 14-26, 1986, Greece. 
[6] Korc-Grodzicki, B., Tauber-Finkelstein, M. and Shaltiel, 
S. (1988) Proc. Natl. Acad. Sci. USA, 85, 7541-7544. 
[7] Beavo, J.A., Bechtel, P.J. and Krebs, E.G. (1974) 
Methods Enzymol. 38C, 299-308. 
[8] Warner, N.L., Harris, A.W. and Gutman, G.A. (1975) 
in: Membrane Receptors of Lymphocytes (Seligmann, M. 
et al. eds) pp.203-216, North-Holland/American 
Elsevier , Amsterdam. 
[l I] Yakir, Y., Kook, A.I., Schlesinger, M. and Trainin, M. 
(1977) Isr. J. Med. Sci. 13, 1191-1196. 
[12] Gilman, A.G. (1970) Proc. Natl. Acad. Sci. USA 67, 
305-312. 
[13] Brown, B.L., Albano, J.D.M., Ekins, R.P., Sgherzi, 
A.M. and Tampion, W. (1971) Biochem. J. 121,561-562. 
[14] Zick, Y., Cesla, R. and Shaltiel, S. (1979) J. Biol. Chem. 
254, 879-887. 
[15] Nagatsu, T. (1973) Biochemistry of Catecholamines, 
pp.209-234, University of Tokyo Press, Tokyo. 
[16] Laemmli, U.K. (1970) Nature 227, 680-685. 
[17] Beebe, S.J. and Corbin, J.D. (1986) The Enzymes 17, 
43-111. 
[18] Walsh, D.A., Perkins, J.P. and Krebs, E.G. (1968) J. 
Biol. Chem. 243, 3763-3765. 
[19] Russell, T.R., Terasaki, W.L. and Appleman, M.M. 
(1974) J. Biol. Chem. 248, 1334-1340. 
[20] Darnell, J.E., Lodish, H. and Baltimore, D. (1986) 
Molecular Cell Biology, pp.667-713, Scientific American 
Books. New York. 
250 
